Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 2353390 | HLA IDENTICAL (HLA-IDENTICAL) | acute myelogenous leukemia | NA | NA | NA | unclassified | |
| marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or hla-identical sibling donor, for aplastic anemia, acute myelogenous or lymphoblastic leukemia that has relapsed once, and is commonly employed for the treatment of acute myelogenous leukemia in the first remission, for chronic myelogenous leukemia in the chronic phase, and for certain congenital disorders. | |||||||
| 2353390 | HLA IDENTICAL (HLA-IDENTICAL) | relapse | NA | NA | NA | unclassified | |
| marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or hla-identical sibling donor, for aplastic anemia, acute myelogenous or lymphoblastic leukemia that has relapsed once, and is commonly employed for the treatment of acute myelogenous leukemia in the first remission, for chronic myelogenous leukemia in the chronic phase, and for certain congenital disorders. | |||||||
| 2353390 | HLA IDENTICAL (HLA-IDENTICAL) | chronic myelogenous leukemia | NA | NA | NA | unclassified | |
| marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or hla-identical sibling donor, for aplastic anemia, acute myelogenous or lymphoblastic leukemia that has relapsed once, and is commonly employed for the treatment of acute myelogenous leukemia in the first remission, for chronic myelogenous leukemia in the chronic phase, and for certain congenital disorders. | |||||||
| 2353390 | HLA IDENTICAL (HLA-IDENTICAL) | lymphoblastic leukemia | NA | NA | NA | unclassified | |
| marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or hla-identical sibling donor, for aplastic anemia, acute myelogenous or lymphoblastic leukemia that has relapsed once, and is commonly employed for the treatment of acute myelogenous leukemia in the first remission, for chronic myelogenous leukemia in the chronic phase, and for certain congenital disorders. | |||||||
| 2353390 | HLA IDENTICAL (HLA-IDENTICAL) | congenital disorders | NA | NA | NA | unclassified | |
| marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or hla-identical sibling donor, for aplastic anemia, acute myelogenous or lymphoblastic leukemia that has relapsed once, and is commonly employed for the treatment of acute myelogenous leukemia in the first remission, for chronic myelogenous leukemia in the chronic phase, and for certain congenital disorders. | |||||||
| 2353390 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| the results of transplantation from hla-nonidentical donors appears promising, but the follow-up is short at this time. | |||||||
| 2368134 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| by examining rates of graft loss within consecutive posttransplant intervals, using data from the uk transplant service, we show that the long-term benefits of hla matching are due to reduction of the graft failure rate within five months of transplantation. | |||||||
| 2368134 | HLA (HLA) | kidney transplantation | NA | NA | NA | unclassified | |
| many studies have shown long-term benefits of hla matching in kidney transplantation. | |||||||
| 2368135 | HLA-DR (HLA-DR) | transplantation | NA | NA | NA | negation | |
| by analyzing the effect of matching on first transplants from unrelated donors in specific intervals up to 3 years posttransplantation, we show that the effect of hla-dr matching is strongest in the first 5 months following transplantation (relative risks of graft failure 1.31 and 1.77 for 1 and 2 hla-dr mismatches, respectively, compared with no mismatches). | |||||||
| 2368135 | HLA-DR (HLA-DR) | transplantation | NA | NA | NA | positive+negation | |
| for patients whose grafts remained functioning after 5 months, there was no significant further improvement in graft survival to 3 years (relative risks 1.16 and 0.98 for 1 and 2 hla-dr mismatches, respectively, compared with no mismatches)--i.e., the gain in graft survival by matching for hla-dr appears to be due to its influence in the first 5 months following transplantation. | |||||||
Copyright 2024